EverspanComparisons
Intervention Comparisons
Head-to-head analysis of the most commonly confused longevity interventions. Evidence-graded, section-by-section, with clear verdicts.
NR wins on evidence depth and safety track record. NMN has a potential bioavailability edge — worth trying if budget allows.
Metformin has deeper evidence but requires a prescription; berberine achieves similar AMPK activation OTC.
Neither alone is optimal — Zone 2 builds the aerobic base, HIIT drives VO2max. The evidence says do both.
Metformin wins for most people — grade A human evidence, 60 years of safety data, accessible by prescription. Rapamycin is more potent in animal models but carries immune-suppression risks that make it a higher-stakes bet.
Quercetin's senolytic evidence (especially with dasatinib) is more mechanistically compelling than resveratrol's SIRT1 story for longevity.
Glycine wins for most people — a fraction of the cost, stronger glycine-specific longevity data, and no animal sourcing concerns. Collagen may add joint-specific peptides at a premium.
Glycinate wins as a daily foundation — corrects deficiency systemically, costs 4× less, and improves sleep quality. Threonate is worth adding specifically if cognitive performance is the priority.
Fish oil has the deeper evidence base and provides more EPA/DHA per dollar; krill oil's phospholipid advantage doesn't justify the cost premium for most users.
About These Comparisons
Each comparison is written by reviewing primary clinical literature and is scored section-by-section on mechanism, human evidence, bioavailability, safety, and cost. Verdicts reflect the current state of evidence and are updated as new research emerges. These pages are educational only — consult a physician before starting any intervention.